Shares of vaccine stocks are trading higher following a report indicating FDA advisers will consider if COVID-19 vaccines should target the LP.8.1 subvariant for 2025-2026.

+0.84%

-4.66%

-5.06%

-1.46%

BioNTech BNTX	0.00	0.00%
Moderna MRNA	0.00	0.00%
Novavax, Inc. NVAX	0.00	0.00%
Pfizer Inc. PFE	0.00	0.00%

Shares of vaccine stocks are trading higher following a report indicating FDA advisers will consider if COVID-19 vaccines should target the LP.8.1 subvariant for 2025-2026.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

BioNTech Raises FY2025 Sales Guidance from $1.787B-$2.314B to $3.040B-$3.274B

Moderna Has Dosed The First Patient In A Phase 1/2 Study Of mRNA-2808, The Company's Investigational Mrna-based T-cell Engager For Relapsed Or Refractory Multiple Myeloma

Pfizer files second lawsuit against Metsera, Novo Nordisk

How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings

UPDATE 5-Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit

BRIEF-Pfizer And Novo Nordisk Sweeten Offers For Metsera As Bidding War Intensifies - FT

Novo Nordisk sweetens bid for Metsera with an offer of up to $10 billion

Is Novavax a Potential Bargain After New Funding and a 16% Share Price Drop?